New Eliquis And Pradaxa Filings Promise To AMPLIFY Competition In VTE
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol reports positive data for Eliquis in the AMPLIFY study, paving the way for new VTE filings. Boehringer recently finally filed its competing Pradaxa in VTE treatment and prevention indications in Europe.